Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7

Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7...

Full description

Saved in:
Bibliographic Details
Main Authors ABBASOVA SVETLANA, KREIMER DAVID, KIM ELDAR, ULITIN ANDREY, MIKHAYLOV ROMAN, VASILYEVA VIKTORIIA, SOLOVYEV VALERY, RIMKEVICH OLGA, MIRZABEKO TAJIB
Format Patent
LanguageEnglish
Published 03.12.2015
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7 receptor in biological samples for diagnostic or evaluative purposes. Fully human antibodies against human CCR7 therefore can be used to diagnose disorders involving CCR7. Further, antibodies of this invention can be useful for treating disorders involving CCR7 by inhibiting binding of native chemokines to the CCR7, and thereby decrease effects of those chemokines. Anti-CCR7 antibodies of this invention can also be used as specific targeting agents to bring toxic agents to CCR7-expressing cells, to inhibit chemotaxis, and therefore can be effective therapeutic agents.
Bibliography:Application Number: US201314404701